Small molecules targeting protein-protein interactions for cancer therapy

被引：28

作者：

Wu, Defa ^{[1
,2
,3
]}

Li, Yang ^{[1
,2
,3
]}

Zheng, Lang ^{[1
,2
,3
]}

Xiao, Huan ^{[1
,2
,3
]}

Ouyang, Liang ^{[1
,2
,3
]}

Wang, Guan ^{[1
,2
,3
]}

Sun, Qiu ^{[1
,2
,3
,4
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu 610041, Peoples R China

[2] Sichuan Univ, West China Hosp, Innovat Ctr Nursing Res, State Key Lab Biotherapy, Chengdu 610041, Peoples R China

[3] Sichuan Univ, West China Sch Nursing, Chengdu 610041, Peoples R China

[4] Sichuan Univ, West China Hosp, West China Med Publishers, Chengdu 610041, Peoples R China

来源：

ACTA PHARMACEUTICA SINICA B | 2023年 / 13卷 / 10期

基金：

中国国家自然科学基金;

关键词：

Protein-protein interactions; Cancer; Small molecules; Structure-activity relationships; STRUCTURE-BASED DESIGN; MICROTUBULE-STABILIZING AGENTS; NF-KAPPA-B; STRUCTURAL BASIS; C-MYC; MDM2; INHIBITOR; BINDING-SITES; CELL-DEATH; IAP PROTEINS; P53; PATHWAY;

D O I：

10.1016/j.apsb.2023.05.035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Protein-protein interactions (PPIs) are fundamental to many biological processes that play an important role in the occurrence and development of a variety of diseases. Targeting the interaction between tumour-related proteins with emerging small molecule drugs has become an attractive approach for treatment of human diseases, especially tumours. Encouragingly, selective PPI-based therapeutic agents have been rapidly advancing over the past decade, providing promising perspectives for novel therapies for patients with cancer. In this review we comprehensively clarify the discovery and development of small molecule modulators of PPIs from multiple aspects, focusing on PPIs in disease, drug design and discovery strategies, structure-activity relationships, inherent dilemmas, and future directions.

引用

页码：4060 / 4088

页数：29

共 50 条

[21] Strategies for converting turn-motif and cyclic peptides to small molecules for targeting protein-protein interactions
Hayward, Deanne
Beekman, Andrew M.
RSC CHEMICAL BIOLOGY, 2024, 5 (03): : 198 - 208
[22] Targeting Protein-Protein Interactions for Anti-Cancer Therapeutics
Blevins, M.
Zhang, Q.
Zhao, R.
BIOPOLYMERS, 2013, 100 (03) : 245 - 246
[23] An approach for targeting protein-protein interactions
Fesik, S.
EJC SUPPLEMENTS, 2008, 6 (12): : 82 - 82
[24] Targeting protein–protein interactions for cancer therapy
David C. Fry
Lyubomir T. Vassilev
Journal of Molecular Medicine, 2005, 83 : 955 - 963
[25] Drugs targeting protein-protein interactions
Chene, Patrick
CHEMMEDCHEM, 2006, 1 (04) : 400 - 411
[26] Approaches to targeting protein-protein interactions
Arkin, Michelle
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
[27] Interfering with protein-protein interactions - Potential for cancer therapy
Tanaka, Tomoyuki
Rabbitts, Terence H.
CELL CYCLE, 2008, 7 (11) : 1569 - 1574
[28] Modulating Protein-Protein Interactions with Small Molecules: The Importance of Binding Hotspots
Thangudu, Ratna Rajesh
Bryant, Stephen H.
Panchenko, Anna R.
Madej, Thomas
JOURNAL OF MOLECULAR BIOLOGY, 2012, 415 (02) : 443 - 453
[29] Systematic Targeting of Protein-Protein Interactions
Modell, Ashley E.
Blosser, Sarah L.
Arora, Paramjit S.
TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (08) : 702 - 713
[30] Targeting epigenetic protein-protein interactions with small-molecule inhibitors
Linhares, Brian M.
Grembecka, Jolanta
Cierpicki, Tomasz
FUTURE MEDICINAL CHEMISTRY, 2020, 12 (14) : 1305 - 1326

← 1 2 3 4 5 →